Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825186 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL16220833 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL32667790 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29477517 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15825187 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL17345690 | 0.95 | PRMT5 (0.90) | PRMT5WDR77 | |
| SCHEMBL21299856 | 0.95 | PRMT5 (0.90) | PRMT5WDR77 | |
| SCHEMBL19125425 | 0.94 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL25059561 | 0.93 | PRMT5 (0.91) | PRMT5WDR77 | |
| SCHEMBL17308471 | 0.93 | PRMT5 (0.91) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| CN-119709590-A | Culture solution and method for transdifferentiation of airway epithelial cells into lung progenitor cells | 中国科学院遗传与发育生物学研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-119684280-A | Targeting protein arginine methylation proximity-induced small molecule chimeric platform MeTAG and application thereof | 西安交通大学医学院第一附属医院 | 2025-03-25 | — | — | CN | claimed |
| US-20250009740-A1 | METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM ALONG WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIC ACTIONS | OHIO STATE INNOVATION FOUNDATION | 2025-01-09 | — | — | US | claimed |
| EP-4436579-A1 | METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM ALONG WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIC ACTIONS | Ohio State Innovation Foundation (US) | 2024-10-02 | — | — | EP | claimed |
| WO-2024177416-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING EGFR TARGETED THERAPY-RESISTANT CANCER | 단국대학교 천안캠퍼스 산학협력단 | 2024-08-29 | — | — | WO | claimed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-115778959-B | Application of compound EPZ015666 in preparation of medicines for preventing and treating fibrosis-related diseases | 江南大学 | 2024-05-28 | — | — | CN | claimed |
| CN-113186153-B | Application of PRMT5 inhibitor in promoting regeneration and proliferation of spermatogonial stem cell injury | 南方医科大学 | 2023-09-08 | — | — | CN | claimed |
| CN-116271036-A | Application of PRMT5 inhibitor in preparation of medicine for treating drug-resistant solid tumor | 天津大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230190707-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2023-06-22 | — | — | US | claimed |
| CN-116211869-A | Pharmaceutical mixture containing DNA damage repair inhibitor, mixing method and application | 浙江省肿瘤医院 | 2023-06-06 | — | — | CN | claimed |
| CN-116196415-A | Mixed formulations for sensitizing PD-1 antibodies and methods of use thereof | 浙江省肿瘤医院 | 2023-06-02 | — | — | CN | claimed |
| WO-2023091793-A1 | METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM ALONG WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIC ACTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-25 | — | — | WO | claimed |
| CN-113476450-B | Application of EPZ015666 in preparation of medicine for preventing and treating vascular intimal hyperplasia diseases | 江南大学 | 2023-04-28 | — | — | CN | claimed |
| EP-4149483-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | Fred Hutchinson Cancer Center (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115778959-A | Application of compound EPZ015666 in preparation of medicines for preventing and treating fibrosis-related diseases | 江南大学 | 2023-03-14 | — | — | CN | claimed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | claimed |
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | PRMT5 7/4885WDR77 146/4885 |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | PRMT5 356/4885WDR77 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.